119th Congress
S. 1186
Lower Drug Costs for Families Act
- Introduced
- In committee
- Passed Senate
- Passed House
- To President
- Became law
- Sponsor
- Catherine Cortez Masto(D-NV)
- Introduced
- Mar 27, 2025
- Policy area
- Health
- Committees
- Senate Committee on Finance
- Official text
- Introduced in Senate · Congress.gov page
Cosponsors (13)
Original cosponsors (11)
- Amy Klobuchar (D-MN)
- Angus S. King, Jr. (I-ME)
- Elissa Slotkin (D-MI)
- Jack Reed (D-RI)
- John W. Hickenlooper (D-CO)
- Peter Welch (D-VT)
- Richard Blumenthal (D-CT)
- Ron Wyden (D-OR)
- Ruben Gallego (D-AZ)
- Tammy Baldwin (D-WI)
- Tina Smith (D-MN)
Added later (2)
- Ben Ray Luján (D-NM) · Apr 1, 2025
- Jeff Merkley (D-OR) · Jun 2, 2026
Summary
Summary by the Congressional Research Service· describes the “Introduced in Senate” version
Lower Drug Costs for Families Act
This bill applies certain Medicare prescription drug rebate requirements to prescription drugs that are available under private health insurance.
Current law requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services for brand-name drugs without generic equivalents under Medicare that (1) cost $100 or more per year per individual, and (2) for which prices increase faster than inflation. Manufacturers that fail to comply are subject to civil penalties.
The bill applies these requirements to prescription drugs that are available in the commercial market under private health insurance. It also indexes rebate calculations to drug prices in 2016 (as opposed to 2021).
Roll-call votes
No recorded votes on this bill.
Actions
- Mar 27, 2025 · Senate
Read twice and referred to the Committee on Finance. - Mar 27, 2025
Introduced in Senate